Pemigatinib Peimeidx 4.5mg: FGFR2-Selected Therapy for Cholangiocarcinoma

Overview

Not every biliary tract tumor responds to the same approach, so pemigatinib is reserved for a clearly defined population: previously treated, unresectable or metastatic cholangiocarcinoma whose tumor carries an FGFR2 fusion or rearrangement. This biomarker-selected framing matters because the drug's activity is concentrated in that molecular subgroup. Confirmation comes from an approved companion diagnostic before therapy begins. Matching the right patient to the right inhibitor, rather than treating all biliary cancers alike, is the central idea behind how this agent is used in routine oncology practice today.

How It Works

Pemigatinib is a selective inhibitor of FGFR1, FGFR2 and FGFR3. It competes for the adenosine-triphosphate binding site on the receptor, blocking autophosphorylation and the downstream FRS2 and MAPK pathway that drives proliferation in FGFR2-rearranged cells. By shutting off this specific survival signal, the tumor's growth dependence on the altered receptor is exposed, and cells that relied on FGFR signaling lose their proliferative advantage while normal tissue is comparatively spared the same pressure.

Indications

• Previously treated unresectable locally advanced or metastatic cholangiocarcinoma
• Tumor with a confirmed FGFR2 fusion or rearrangement by an approved companion diagnostic
• Adults who have progressed on or after prior systemic therapy

Dosage & Administration

The standard plan is 13.5 mg once daily, equal to three 4.5 mg tablets, taken on a 21-days-on and 7-days-off schedule within each 28-day cycle. Tablets are swallowed whole with water and continued until disease progression or unacceptable toxicity. Dose holds or reductions manage elevated phosphate and other lab changes under clinician supervision, and the regular off-week helps some patients recover from cumulative side effects between treatment blocks.

Storage & Sourcing

Store at 20 to 25°C, protected from light, in the original packaging. Supplied through Innovent and Incyte partner lines with lot-specific certificates of analysis. As an oral solid it is ambient stable, which simplifies distribution to oncology pharmacies and cross-border B2B supply while keeping batch traceability intact for audit and pharmacovigilance needs.

FAQ

Q: Who is the right patient for pemigatinib?

A: Adults with previously treated, unresectable or metastatic cholangiocarcinoma whose tumor shows an FGFR2 fusion or rearrangement on an approved companion diagnostic test.

Q: Why is biomarker testing required first?

A: The drug works mainly in FGFR2-altered tumors; testing avoids exposing non-selected patients to toxicity without benefit and steers them toward the therapy most likely to help.

Q: How is the dose taken across a cycle?

A: The regimen is 13.5 mg daily, three 4.5 mg tablets, for 21 days followed by 7 days off, repeating every 28 days until progression or limiting toxicity.

Q: What eye care is recommended?

A: Baseline and periodic ophthalmologic exams are advised because retinal pigment epithelium changes can occur; any new vision change should be reported promptly.